At Fox Chase Cancer Center and Temple University Hospital, it’s “in the blood” of our residents and Fellows to develop innovative scientific ideas that significantly affect the way blood diseases are diagnosed and treated. Here is the latest from ASH 2025:

Helen Gandler, MD, a third-year internal medicine resident at Temple Hospital and first author for an ASH-presented poster, demonstrated that a routine absolute lymphocyte count (ALC) was predictive of which patients with non-Hodgkin’s lymphoma would benefit from CAR T-Cell therapy. READ MORE

Asya Varshavsky-Yanovsky, MD, PhD, former Hematology/Oncology Fellow and Associate Professor, Fox Chase Blood Cancer and Cellular Therapy Institute, presented a study showing that T-cell redirecting therapy can be monitored at home, potentially eliminating routine hospitalization after CAR T and BiTE treatments, with no adverse safety events. READ MORE